Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Versus Clopidogrel for Leaflet Thrombosis Prevention After TAVR
NCT05493657Recruiting
- Sponsor
- Yonsei University
- Start
- Feb 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of clopidogrel in Leaflet thrombosis (2 arms), sponsored by Yonsei University. Primary endpoint: Incidence of leaflet thrombosis on cardiac CT at 3 months. Started Feb 2023; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
Leaflet thrombosis
Beyond the preview
Go deeper on NCT05493657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493657.